PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-20.50%
Negative revenue growth while CVE stands at 9.12%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-37.39%
Negative gross profit growth while CVE is at 58.71%. Joel Greenblatt would examine cost competitiveness or demand decline.
-101.25%
Negative EBIT growth while CVE is at 177.22%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-101.25%
Negative operating income growth while CVE is at 177.22%. Joel Greenblatt would press for urgent turnaround measures.
-11.18%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-11.76%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-11.76%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.01%
Share reduction more than 1.5x CVE's 10.37%. David Dodd would see if the company is taking advantage of undervaluation to retire shares.
0.01%
Diluted share reduction more than 1.5x CVE's 10.37%. David Dodd would validate if the company is aggressively retiring shares or limiting option exercises.
-0.01%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
63.76%
Positive OCF growth while CVE is negative. John Neff would see this as a clear operational advantage vs. the competitor.
41.12%
Positive FCF growth while CVE is negative. John Neff would see a strong competitive edge in net cash generation.
-88.22%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-36.46%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-71.30%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-87.64%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-76.35%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-60.94%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-75.90%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
117.88%
Positive 5Y CAGR while CVE is negative. John Neff might view this as a strong mid-term relative advantage.
-92.02%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-73.12%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-4.54%
Negative 5Y equity/share growth while CVE is at 18.75%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-44.15%
Negative 3Y equity/share growth while CVE is at 11.45%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-92.85%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-92.80%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-79.09%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
-1.30%
Firm’s AR is declining while CVE shows 2.35%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
No Data
No Data available this quarter, please select a different quarter.
1.03%
Positive asset growth while CVE is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
2.67%
Positive BV/share change while CVE is negative. John Neff sees a clear edge over a competitor losing equity.
0.48%
We have some new debt while CVE reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
23.91%
SG&A declining or stable vs. CVE's 100.00%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.